Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 3
2013 6
2014 11
2015 10
2016 8
2017 4
2018 6
2019 5
2020 4
2021 4
2022 2
2023 3
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials.
Core JQ, Pistilli M, Hua P, Daniel E, Grunwald JE, Toth CA, Jaffe GJ, Martin DF, Maguire MG, Ying GS; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Core JQ, et al. Ophthalmol Retina. 2022 Sep;6(9):771-785. doi: 10.1016/j.oret.2022.03.024. Epub 2022 Apr 9. Ophthalmol Retina. 2022. PMID: 35405352 Free PMC article. Clinical Trial.
Prediction for 2-Year Vision Outcomes Using Early Morphologic and Functional Responses in the Comparison of Age-related Macular Degeneration Treatments Trials.
Xue K, Hua P, Maguire MG, Daniel E, Jaffe GJ, Grunwald JE, Ying GS; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Xue K, et al. Ophthalmol Retina. 2023 Jul;7(7):564-572. doi: 10.1016/j.oret.2023.02.008. Epub 2023 Feb 19. Ophthalmol Retina. 2023. PMID: 36803692 Free PMC article. Clinical Trial.
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Writing Committee:; Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, et al. Ophthalmology. 2020 Apr;127(4S):S135-S145. doi: 10.1016/j.ophtha.2020.01.029. Ophthalmology. 2020. PMID: 32200813 Clinical Trial.
Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Willoughby AS, et al. Ophthalmology. 2015 Sep;122(9):1846-53.e5. doi: 10.1016/j.ophtha.2015.05.042. Epub 2015 Jul 2. Ophthalmology. 2015. PMID: 26143666 Free PMC article. Clinical Trial.
Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Core JQ, Pistilli M, Daniel E, Grunwald JE, Toth CA, Jaffe GJ, Hua P, Martin DF, Ying GS, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Core JQ, et al. Ophthalmol Retina. 2021 Oct;5(10):962-974. doi: 10.1016/j.oret.2021.06.003. Epub 2021 Jun 11. Ophthalmol Retina. 2021. PMID: 34126249 Free PMC article. Clinical Trial.
54 results